Liping Dou
Clinical trials sponsored by Liping Dou, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New CAR-T therapy aims to keep leukemia in remission Results expected Dec 2026 (estimated)
- New CAR-T therapy aims to keep High-Risk leukemia in remission Results expected Dec 2026 (estimated)
- Engineered immune cells aim to deepen remission in lymphoma patients Results expected Jan 2027 (estimated)
- Can engineered immune cells lock in remission for aggressive lymphoma? Results expected Apr 2027 (estimated)
-
Can engineered immune cells lock in remission for aggressive lymphoma?
Disease control Recruiting nowThis phase 2 trial is testing whether a personalized cell therapy called CD22/CD19 CAR-T can help keep aggressive B-cell lymphoma in remission. Patients who achieved a complete response after standard second-line chemotherapy will receive a single infusion of their own geneticall…
Phase 2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Combination therapy aims to keep leukemia in check after transplant
Disease control Recruiting nowThis study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The trea…
Phase 1 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New CAR-T therapy aims to keep leukemia in remission
Disease control Recruiting nowThis study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells aim to deepen remission in lymphoma patients
Disease control Recruiting nowThis study tests a new type of immunotherapy called CD19/CD22 CAR-T cells as an early consolidation treatment for people with follicular lymphoma who still have some disease after standard chemotherapy. About 20 participants will receive a single infusion of their own modified im…
Phase 2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC